Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 16/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7094238 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL679166 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL29397241 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL27484349 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL679165 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL678544 | 1.00 | PRKCA (0.40) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL27660742 | 0.98 | PRKCA (0.38) | PRKCAKDM4ELMNA | |
| SCHEMBL2987621 | 0.93 | CCR6 (0.39) | PRKCAKDM4ELMNATSHR | |
| SCHEMBL679077 | 0.85 | ALDH1A1 (0.39) | — | |
| SCHEMBL679076 | 0.85 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365969-B1 | Novel anti-biofilm agents | YISSUM RES DEV CO (IL) | 2017-03-22 | — | — | EP | claimed |
| EP-2365969-A1 | Novel anti-biofilm agents | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2011-09-21 | — | — | EP | claimed |
| WO-2010058402-A1 | NOVEL ANTI-BIOFILM AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-05-27 | — | — | WO | claimed |
| EP-2365969-B1 | Novel anti-biofilm agents | YISSUM RES DEV CO (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-8865909-B2 | Anti-biofilm agents | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2014-10-21 | — | — | US | disclosed |
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2011-11-17 | — | — | US | disclosed |
| EP-2365969-A1 | Novel anti-biofilm agents | Yissum Research Development Company of The Hebrew University of Jerusalem (IL) | 2011-09-21 | — | — | EP | disclosed |
| WO-2010058402-A1 | NOVEL ANTI-BIOFILM AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281921-A1 | NOVEL ANTI-BIOFILM AGENTS | PYCARD, DNM2, MMP8 | PRKCA 3311/4885KDM4E 1343/4885LMNA 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.